Possible Protective Mechanisms Exerted by Metformin or Metformin and Vitamin E in Isoproterenol-induced Cardiac Injury
Overview
Cell Biology
Authors
Affiliations
Several studies have reported that metformin is cardioprotective for diabetic and non-diabetic ischemic hearts through mechanisms that cannot be entirely attributed to its anti-hyperglycemic effect. This study was designed to investigate the cardioprotective effects of metformin with and without vitamin E after induction myocardial infarction (MI) in rats, using isoproterenol. Administration of metformin or vitamin E significantly reduced the cardiac mass index (P < 0.01), ameliorated the changes to cardiac biomarkers, and attenuated oxidative stress levels compared to the isoproterenol group. Interestingly, combination therapy showed a slight synergistic effect. Histopathological analysis suggested that metformin treatment reduced NF-κB expression and protected against isoproterenol-induced MI. Our results indicate that metformin mediates a cardioprotective effect against isoproterenol-induced MI via antioxidant activity and modulation of the NF-κB signaling pathway. This suggests that metformin would be beneficial in MI treatment.
Agarwal V, Kaushik A, Chaudhary R, Rehman M, Srivastava S, Mishra V Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(1):281-303.
PMID: 37421431 DOI: 10.1007/s00210-023-02611-5.
Badawy M, Elsherbiny M, Elshopakey G, Elsayyad A, El-Kattan M, Hamama M J Toxicol. 2023; 2022:7760594.
PMID: 36601412 PMC: 9807306. DOI: 10.1155/2022/7760594.
Meshkani S, Mahdian D, Abbaszadeh-Goudarzi K, Abroudi M, Dadashizadeh G, Lalau J J Endocrinol Invest. 2019; 43(1):1-19.
PMID: 31098946 DOI: 10.1007/s40618-019-01060-3.